Results of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Abstract highlights biomarker with ability to predict clinical responses of glioblastoma patients to NOX-A12-based thera…
83% of glioblastoma patients remain alive after 14 months on study, a percentage well above what is expected for the enr…
. Selection for presentation by ASCO highlights the strength of TME Pharma’s science and the importance of results eme…
Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial eva…
€2 million new cash secured Termination of the convertible bond agreement by TME Pharma Lock-up of all new shares issued…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…